Evidence map›Paper›PMID 25984609›Full record

ReviewInternational journal of molecular sciences2015

Possibility of breast cancer prevention: use of soy isoflavones and fermented soy beverage produced using probiotics.

Akimitsu Takagi, Mitsuyoshi Kano, Chiaki Kaga

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Quality evaluation ofHeliyon · 2023
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Nutritional andHeliyon · 2022
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Akimitsu TakagiPharmaceutical Research Laboratory, Yakult Central Institute, Tokyo 186-8650, Japan. akimitsu-takagi@yakult.co.jp.
Mitsuyoshi KanoFood Research Laboratory, Yakult Central Institute, Tokyo 186-8650, Japan. mitsuyoshi-kano@yakult.co.jp.
Chiaki KagaFood Research Laboratory, Yakult Central Institute, Tokyo 186-8650, Japan. chiaki-kaga@yakult.co.jp.
Yakult Central Institute · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The various beneficial effects of soybeans, which are rich in phytochemicals, have received much attention because of increasing health awareness. Soy milk that has been fermented using lactic acid bacteria has been used to prepare cheese-like products, tofu (bean-curd), and yogurt-type products. However, the distinct odor of soybeans has limited the acceptance of such foods, particularly in Western countries. In Japan, while tofu and soy milk have long been habitually consumed, the development of novel, palatable food products has not been easy. The unpleasant odor of soy milk and the absorption efficiency for isoflavones can be improved using a recently developed fermented soy milk beverage. Cancer has been the leading cause of death, and breast cancer is the most common malignancy among women. The most common type of breast cancer is estrogen-dependent, and the anti-estrogenic effects of isoflavones are known. The present review focuses on the characteristics of soy milk fermented using probiotics, an epidemiological study examining the incidence of breast cancer and soy isoflavone consumption, and a non-clinical study examining breast cancer prevention using fermented soy milk beverage.

Indexed as

FermentationBreast NeoplasmsFemaleGlycine maxHumansIsoflavonesProbioticsSoy MilkIsoflavonesbreast cancerfermented soy milkisoflavoneL. casei Shirotaprobiotics

Identifiers

PMID25984609
PMCPMC4463682
OpenAlexW1600828823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.